Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + enzastaurin + pemetrexed
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination involves **cisplatin**, a platinum-based chemotherapy drug that interferes with DNA replication; **enzastaurin**, a serine/threonine kinase inhibitor targeting the PI3K/AKT and protein kinase C pathways to suppress tumor cell proliferation and induce apoptosis; and **pemetrexed**, an antifolate antineoplastic agent that inhibits DNA synthesis. The combination aims to enhance antitumor effects by targeting multiple pathways involved in cancer cell growth and survival.
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)PRKCB (Protein kinase C beta)TS (Thymidylate synthase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)PKC (Protein kinase C family)
Beyond the preview
Go deeper on cisplatin + enzastaurin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + enzastaurin + pemetrexed.